//Indee Labs closed a $1.3M angel round

Indee Labs closed a $1.3M angel round

Indee Labs recently closed a $1.3M angel round and demonstrated functional modification of human primary T-cells with high efficiency (30 to 60%), cell viability (>85%) and recovery (>90%) without T-cell exhaustion or activation. The team also signed its first customer — a clinical-stage biotechnology company developing gene-modified B-cell therapies for rare disease — and is collaborating with a notable medical research clinic in the midwest and a private Bay Area research university on both T-cell gene editing and chimeric antigen receptor T-cell (CAR-T) development. Moreover, Indee Labs is regularly invited to present at various events organized by the White House Cancer Moonshot Taskforce, Air Force Office of Scientific Research, Air Force Research Laboratory, National Institutes of Health and National Cancer Institute among others.

2018-09-25T11:08:33+00:00July 3rd, 2017|Alumni News|